Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
MMW Fortschritte Der Medizin|December 12, 2002
[Treatment monitoring, recurrence detection, prognosis. Here's where tumor markers make good sense]R Lamerz, P StieberAnnals of the New York Academy of Sciences|July 15, 2004
Therapy control in oncology by circulating nucleosomesS Holdenrieder, P StieberMMW Fortschritte Der Medizin|June 17, 2005
[Tumor markers--how they should be applied]P Stieber, V Heinemann, A SchalhornCurrent Oncology (Toronto, Ont.)|February 14, 2012
Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancerR Moro, J Gulyaeva-Tcherkassova, P StieberIn Vivo (Athens, Greece)|November 1, 1993
Serum marker combinations in human breast cancer (review)R Lamerz, P Stieber, A Fateh-MoghadamAnticancer Research|July 1, 1997
Value of HAMA--determination in clinical practice--an overviewU Hasholzner, P Stieber, W Meier, et al.Anticancer Research|September 2, 1999
Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseasesR Lamerz, M Runge, P Stieber, et al.Anticancer Research|July 1, 1997
Significance of tumor marker determinations in the primary therapy of ovarian cancerW Meier, L Baumgartner, P Stieber, et al.Anticancer Research|July 1, 1997
Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinomaW Meier, P Stieber, U Hasholzner, et al.Pageof 8